2,230$
1,83%
Echtzeit-Aktienkurs Paratek Pharmaceuticals Inc,
Bid:
Ask:
Echtzeit-Chart der Paratek Pharmaceuticals Inc, Aktie
Börsenkurse Paratek Pharmaceuticals Inc,
Fundamentaldaten der Paratek Pharmaceuticals Inc, Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2022 [USD] | 160,27 Mio. | -63,51 Mio. | -63,57 Mio. | -1,17 | - | - | 0,79 |
| 2021 [USD] | 130,16 Mio. | -58,48 Mio. | -59,08 Mio. | -1,22 | - | - | 0,89 |
| 2020 [USD] | 46,92 Mio. | -96,54 Mio. | -96,54 Mio. | -2,19 | - | - | 2,21 |
| 2019 [USD] | 16,54 Mio. | -128,49 Mio. | -128,79 Mio. | -3,93 | - | - | 5,37 |
| 2018 [USD] | 17,12 Mio. | -111,85 Mio. | -112,36 Mio. | -3,57 | - | - | 4,20 |
| 2017 [USD] | 12,62 Mio. | -88,32 Mio. | -89,07 Mio. | -3,32 | - | - | 4,94 |
| 2016 [USD] | 0,03 Mio. | -111,64 Mio. | -111,64 Mio. | -5,51 | - | - | 1796,20 |
| 2015 [USD] | - | -70,86 Mio. | -70,86 Mio. | -4,29 | - | - | - |
| 2014 [USD] | 4,34 Mio. | -17,84 Mio. | -17,84 Mio. | -7,82 | 1074,83% | - | 7,40 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Paratek Pharmaceuticals Inc, Aktie
Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.